Analysis of U.S. Patent 7,335,799
U.S. Patent 7,335,799, granted on February 26, 2008, to Sanofi-Aventis, U.S. LLC, claims methods for treating and preventing obesity and related metabolic disorders using a combination therapy. The patent focuses on the use of a serotonin 2C receptor agonist in conjunction with a cannabinoid receptor 1 antagonist. This patent's scope is significant, encompassing a broad range of related conditions and therapeutic applications, positioning it as a key asset in the development of anti-obesity therapeutics. The patent landscape surrounding this core claim is complex, with multiple secondary patents and potential challenges influencing market exclusivity.
What is the Core Technology Claimed in U.S. Patent 7,335,799?
The central innovation protected by U.S. Patent 7,335,799 is a combination therapy for managing weight and associated metabolic dysfunctions. Specifically, the patent claims methods of treating obesity, overweight conditions, and other related metabolic disorders by co-administering a serotonin 2C receptor agonist and a cannabinoid receptor 1 (CB1) antagonist.
Serotonin 2C Receptor Agonists
Serotonin 2C receptors are a class of G protein-coupled receptors found in the central nervous system. Activation of these receptors in the hypothalamus is known to reduce appetite and increase satiety. The patent broadly defines serotonin 2C receptor agonists, implying coverage for various chemical entities that activate this receptor.
Cannabinoid Receptor 1 Antagonists
Cannabinoid receptor 1 (CB1) receptors are also predominantly located in the central nervous system and are involved in regulating appetite and energy balance. Blocking these receptors has been shown to decrease food intake and promote weight loss. The patent encompasses CB1 antagonists, suggesting a wide range of compounds capable of inhibiting CB1 receptor activity.
The Combination Therapy
The synergistic effect of combining these two mechanisms is the cornerstone of the patent. By simultaneously targeting appetite-reducing pathways via serotonin 2C receptor activation and appetite-stimulating pathways via CB1 receptor blockade, the claimed method aims to achieve a more effective and sustained reduction in body weight and improvement in metabolic parameters than either agent alone.
What Therapeutic Areas and Conditions Are Covered by the Patent Claims?
U.S. Patent 7,335,799 extends its protection to a wide spectrum of conditions linked to excess body weight, including:
- Obesity: Defined as having a body mass index (BMI) of 30 kg/m² or greater.
- Overweight: Defined as having a BMI between 25 kg/m² and 29.9 kg/m².
- Weight Gain: Including weight gain associated with the use of certain medications, such as antipsychotics.
- Metabolic Syndrome: A cluster of conditions including high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels, which increase the risk of heart disease, stroke, and diabetes.
- Insulin Resistance: A condition where cells in your muscles, fat, and liver don’t respond well to insulin and can’t easily take up glucose from your blood.
- Type 2 Diabetes: A chronic condition that affects the way your body processes blood sugar (glucose), your body’s main source of energy.
- Dyslipidemia: An abnormal amount of cholesterol, fat, or other lipids in the blood.
- Hypertension: High blood pressure.
- Nonalcoholic Fatty Liver Disease (NAFLD): A condition in which excess fat builds up in the liver, unrelated to alcohol consumption.
The broad inclusion of these conditions signifies the patent's intent to cover a comprehensive approach to managing the multifaceted health consequences of obesity.
What is the Specific Formulation or Method of Administration Implied by the Patent?
The patent describes methods of treatment, implying the administration of the serotonin 2C receptor agonist and the CB1 antagonist to a subject in need of such treatment. While the patent does not explicitly detail specific pharmaceutical formulations, it generally refers to the "co-administration" of the two classes of compounds. This suggests that the compounds can be administered separately, sequentially, or as a combined dosage form.
The patent mentions that the serotonin 2C receptor agonist and the CB1 antagonist can be formulated into a single pharmaceutical composition or administered as separate compositions. This flexibility in formulation and administration is crucial for developing various drug products that fall under the patent's protection.
What is the Patent's Exclusivity Period and Key Dates?
Understanding the exclusivity period is critical for determining the remaining market protection.
- Grant Date: February 26, 2008
- Filing Date: January 23, 2003
- Earliest Priority Date: January 24, 2002 (based on U.S. Provisional Application No. 60/351,175)
Under U.S. patent law, the standard patent term is 20 years from the earliest non-provisional filing date, subject to adjustments and extensions.
- Initial Expiration (20-year term): January 23, 2023
It is important to note that patent term adjustments (PTA) or extensions (PTE) could have potentially extended the expiration date. For U.S. Patent 7,335,799, a review of the USPTO patent term calculator or official records is necessary to confirm any granted adjustments or extensions. Without specific information on PTA/PTE, the 20-year term from the filing date serves as the baseline for calculating potential market exclusivity.
What is the Intellectual Property Landscape Surrounding This Patent?
The patent landscape for combination therapies, particularly for complex indications like obesity, is often intricate. U.S. Patent 7,335,799 likely exists within a framework of other intellectual property rights that could include:
- Composition of Matter Patents: Patents covering the specific chemical structures of the serotonin 2C receptor agonists and CB1 antagonists used in the claimed methods. These patents would typically have longer exclusivity periods than method-of-use patents.
- Formulation Patents: Patents claiming specific ways to combine and deliver the active pharmaceutical ingredients (APIs), such as particular tablet formulations, controlled-release mechanisms, or delivery devices.
- Method of Use Patents: Other patents claiming specific applications or patient populations for the combination therapy.
- Secondary Patents: Patents filed after the priority date of 7,335,799 that might claim improvements or specific embodiments of the combination therapy.
Key Players and Compounds
Sanofi-Aventis (now Sanofi) was the assignee of this patent. The development and commercialization of obesity drugs are highly competitive. Key compounds investigated in the past that involve these receptor targets include:
- Serotonin 2C Receptor Agonists: Phentermine is a well-known anorectic that acts on serotonin pathways. Lorcaserin (Belviq), developed by Arena Pharmaceuticals and later acquired by Eisai, was a selective serotonin 2C receptor agonist specifically approved for weight management.
- Cannabinoid Receptor 1 Antagonists: Rimonabant (Acomplia), developed by Sanofi-Aventis, was a CB1 antagonist approved in Europe for obesity but later withdrawn due to psychiatric side effects.
The combination claimed in 7,335,799 was likely developed with specific compounds in mind, even if the patent claims them broadly. The commercialization efforts, if any, for this specific combination would have been influenced by the success and challenges encountered by individual agents.
What Are Potential Challenges and Opportunities for This Patent?
The primary challenges and opportunities associated with U.S. Patent 7,335,799 are:
Challenges
- Expiration of Core Patent: As noted, the 20-year term from the filing date has likely expired or is nearing expiration, diminishing its primary defensive value.
- Evergreening Strategies: Competitors may seek to design around the patent by developing new compounds or formulations that do not infringe the original claims, or by leveraging newer patent filings for related technologies.
- Clinical Efficacy and Safety of Combination Therapies: The development of safe and effective weight-loss drugs has historically been fraught with challenges, including side effects and patient adherence. The efficacy and safety profile of any specific combination therapy would be a critical factor.
- Patent Litigation: The patent could be subject to challenges in the form of inter partes review (IPR) proceedings at the USPTO or invalidity defenses in infringement lawsuits, seeking to invalidate its claims.
Opportunities
- Data Exclusivity: Even after patent expiration, regulatory data exclusivity periods (e.g., 5 years for new chemical entities under the Hatch-Waxman Act) can provide additional market protection for the first approved drug utilizing the patented technology.
- New Formulations and Delivery Methods: The patent holder could have pursued secondary patents on novel formulations or delivery systems for the combination therapy, extending exclusivity for specific product configurations.
- Combination with Newer Agents: The foundational patent may inform the development of future combination therapies, where one component is a derivative of a molecule covered by the patent, or a new agent is combined with a previously patented agent.
- Treatment of Specific Patient Subgroups: Further research and patent filings might focus on the efficacy of the combination in specific patient populations with comorbidities, potentially leading to new method-of-use patents.
What is the Significance of This Patent in the Broader Context of Obesity Treatment?
U.S. Patent 7,335,799 represents a strategic effort by Sanofi-Aventis to claim a significant therapeutic approach to obesity. At the time of its filing and grant, the landscape for pharmacologic obesity treatment was evolving. While earlier treatments existed, there was a significant unmet need for more effective and safer long-term solutions.
The patent's focus on targeting two distinct neurochemical pathways involved in appetite regulation reflects a sophisticated understanding of the neurobiology of obesity. The inclusion of numerous metabolic disorders underscores the recognition that obesity is not merely an aesthetic concern but a complex medical condition with widespread health implications.
The patent's lifespan coincided with a period of intense research and development in obesity pharmacotherapy. The challenges faced by drugs like rimonabant and lorcaserin, despite their individual mechanisms, highlight the difficulty in translating scientific understanding into successful clinical products. This patent, therefore, is a landmark in the pursuit of pharmacologic obesity solutions, representing a specific combinatorial strategy explored during this critical research phase.
How Does This Patent Relate to Existing and Future Obesity Therapeutics?
The principles behind U.S. Patent 7,335,799 continue to influence the development of obesity therapeutics. While the patent itself may have expired, the concept of targeting multiple pathways concurrently remains a central strategy.
- Current Obesity Drugs: Modern obesity medications often employ multi-target approaches. For example, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are GLP-1 receptor agonists that also impact appetite through brain pathways and may have effects on other metabolic hormones. While not directly derived from 7,335,799, they exemplify the trend towards modulating central appetite control.
- Future Research: Future research may explore combinations that include agents targeting not only serotonin and cannabinoid receptors but also other pathways such as those involving leptin, ghrelin, or melanocortins, as well as novel targets identified through advancements in genetics and molecular biology. The insights gained from patents like 7,335,799 contribute to the foundational knowledge informing these future developments.
The patent's expiration opens avenues for generic manufacturers to enter the market with treatments that fall within the scope of its claims, provided no other valid patents or regulatory exclusivities are in place. However, the ongoing innovation in obesity treatment suggests that the therapeutic landscape will continue to evolve, with new patented combinations and single agents emerging.
Key Takeaways
- U.S. Patent 7,335,799 claims a combination therapy for treating obesity and related metabolic disorders using a serotonin 2C receptor agonist and a cannabinoid receptor 1 antagonist.
- The patent broadly covers a wide range of conditions including obesity, overweight, metabolic syndrome, insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and NAFLD.
- The patent's initial 20-year term from its filing date of January 23, 2003, suggests an expiration around January 23, 2023, although potential adjustments or extensions require specific verification.
- The intellectual property landscape is complex, involving potential secondary patents on specific compounds, formulations, and narrower methods of use.
- The patent's expiration presents opportunities for generic competition but also highlights the ongoing challenges in developing and commercializing safe and effective obesity treatments.
- The principles of multi-pathway targeting, as exemplified by this patent, continue to inform the development of current and future obesity therapeutics.
Frequently Asked Questions
-
Has U.S. Patent 7,335,799 expired?
The standard 20-year patent term from the filing date of January 23, 2003, would suggest expiration around January 23, 2023. However, specific U.S. Patent Term Adjustments (PTA) or Patent Term Extensions (PTE) granted by the USPTO could have altered this date. A definitive expiration date requires consulting official USPTO records or a patent term calculator.
-
What specific drugs were intended to be covered by this patent?
The patent claims classes of compounds (serotonin 2C receptor agonists and CB1 antagonists) rather than specific drug names. While Sanofi-Aventis was the assignee and had developed rimonabant (a CB1 antagonist), the patent language is broad enough to encompass various molecules fitting these receptor classifications, developed by any entity, if used in the claimed combination method.
-
Can a company now legally sell a combination therapy for obesity based on the claims of U.S. Patent 7,335,799?
If the patent has expired and there are no other overlapping patents or regulatory exclusivities (e.g., for new chemical entities or specific formulations), then a company may be able to market such a combination. However, thorough freedom-to-operate (FTO) analysis is required to ensure no infringement of other active patents or market exclusivities.
-
What is the primary mechanism of action for the combination therapy claimed in the patent?
The combination therapy aims to treat obesity and related disorders by simultaneously: 1) reducing appetite and increasing satiety through the activation of serotonin 2C receptors in the brain, and 2) decreasing food intake and promoting weight loss by blocking cannabinoid receptor 1 (CB1) activity.
-
Are there any known side effects associated with the classes of drugs claimed in this patent?
Yes. Serotonin 2C receptor agonists can cause side effects like headache, nausea, and dry mouth. Cannabinoid receptor 1 antagonists, particularly rimonabant, were withdrawn from the market due to significant psychiatric side effects, including depression and suicidal ideation, indicating potential safety concerns with this class of compounds.
Citations
[1] Sanofi-Aventis, U.S. LLC. (2008). Method of treating and preventing obesity and metabolic disorders (U.S. Patent No. 7,335,799). United States Patent and Trademark Office.
